CDC advisers review blood-clotting risk associated with J&J’s covid-19 vaccine
Live MintU.S. vaccine advisers are scheduled to consider whether to change recommendations on the use of Johnson & Johnson’s Covid-19 vaccine because of the risk of a rare but serious blood-clotting condition. The Advisory Committee on Immunization Practices will hear updates Thursday from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels. Earlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the rare condition, known as thrombosis with thrombocytopenia syndrome, or TTS. Partly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna Inc. and Pfizer Inc. with its partner BioNTech SE.